[HTML][HTML] Inhibition of NaV1.8 prevents atrial arrhythmogenesis in human and mice
S Pabel, S Ahmad, P Tirilomis, T Stehle… - Basic Research in …, 2020 - Springer
Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
Inhibition of NaV1. 8 prevents atrial arrhythmogenesis in human and mice
P Steffen, S Ahmad, T Petros, S Thea… - Basic Research in …, 2020 - search.proquest.com
Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
Inhibition of NaV1.8 prevents atrial arrhythmogenesis in human and mice.
S Pabel, S Ahmad, P Tirilomis… - Basic Research in …, 2020 - search.ebscohost.com
Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
Inhibition of NaV1. 8 prevents atrial arrhythmogenesis in human and mice
S Pabel, S Ahmad, P Tirilomis… - Basic Research in …, 2020 - epub.uni-regensburg.de
Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
[HTML][HTML] Inhibition of NaV1. 8 prevents atrial arrhythmogenesis in human and mice
S Pabel, S Ahmad, P Tirilomis, T Stehle… - Basic Research in …, 2020 - ncbi.nlm.nih.gov
Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
Inhibition of NaV1. 8 prevents atrial arrhythmogenesis in human and mice
S Pabel, S Ahmad, P Tirilomis… - Basic research in …, 2020 - pubmed.ncbi.nlm.nih.gov
Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
Inhibition of NaV1.8 prevents atrial arrhythmogenesis in human and mice.
S Pabel, S Ahmad, P Tirilomis, T Stehle… - Basic Research in …, 2020 - europepmc.org
Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
[PDF][PDF] Inhibition of Na
S Pabel, S Ahmad, P Tirilomis, T Stehle… - Basic Research in …, 2020 - scholar.archive.org
Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
[PDF][PDF] Inhibition of Na
S Pabel, S Ahmad, P Tirilomis, T Stehle… - Basic Research in …, 2020 - researchgate.net
Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
Inhibition of NaV1. 8 prevents atrial arrhythmogenesis in human and mice
S Pabel, S Ahmad, P Tirilomis, T Stehle… - 2020 - publications.goettingen-research …
Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …
effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical …